STRO

Sutro Biopharma Inc

May 15 • 04:00PM ET

38.97

+0.55 1.43 %

Healthcare • Biotechnology • USA • Small • NASD

May 14, 6:16 PMSutro Biopharma Inc reports fiscal Q1 2026 results with non-GAAP EPS $-2.94 (+68% YoY) and revenue $14.5M (-17% YoY), misses EPS but beats revenue estimates

Peers: ADCT ALLO FATE ARVN RCUS

| Held by: VTI VXF IWC PRFZ WCEO BTEC CHNA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-16.45	Insider Own	3.84%	Shs Outstand	16.57M	Perf Week	-3.16%
Market Cap	645.75M	Forward P/E	-	EPS next Y	-7.29	Insider Trans	0.00%	Shs Float	15.93M	Perf Month	32.78%
Enterprise Value	685.93M	PEG	-	EPS next Q	-2.53	Inst Own	73.62%	Short Float	6.13%	Perf Quarter	141.15%
Income	-153.60M	P/S	6.48	EPS this Y	60.01%	Inst Trans	-5.75%	Short Ratio	4.64	Perf Half Y	380.58%
Sales	99.61M	P/B	-	EPS next Y	18.95%	ROA	-54.53%	Short Interest	0.98M	Perf YTD	236.82%
Book/sh	-4.04	P/C	3.19	EPS next 5Y	31.55%	ROE	-1810.01%	52W High	41.88 -6.95%	Perf Year	343.60%
Cash/sh	12.22	P/FCF	-	EPS past 3/5Y	1.45% -17.92%	ROIC	-91.29%	52W Low	6.74 478.53%	Perf 3Y	-33.72%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	14.78% 19.12%	Gross Margin	93.27%	Volatility	9.12% 8.79%	Perf 5Y	-80.20%
Dividend TTM	-	EV/Sales	6.89	EPS Y/Y TTM	44.76%	Oper. Margin	-87.44%	ATR (14)	3.02	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.12	Sales Y/Y TTM	49.94%	Profit Margin	-154.21%	RSI (14)	64.07	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	3.12	EPS Q/Q	67.82%	SMA20	5.44%	Beta	1.64	Target Price	46.55
Payout	-	Debt/Eq	-	Sales Q/Q	-16.53%	SMA50	31.01%	Rel Volume	1.24	Prev Close	38.42
Employees	137	LT Debt/Eq	-	Earnings	May 14 AMC	SMA200	147.50%	Avg Volume	210.45K	Price	38.97
IPO	Sep 27, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-7.44% 63.32%	Trades		Volume	260,983	Change	1.43%

Date	Action	Analyst	Rating Change	Price Target Change
May-15-26	Upgrade	Wedbush	Neutral → Outperform	$60
Apr-30-26	Initiated	Mizuho	Outperform	$50
Apr-07-26	Initiated	Leerink Partners	Outperform	$38
Mar-24-26	Upgrade	Wells Fargo	Equal Weight → Overweight	$27
Mar-24-26	Upgrade	H.C. Wainwright	Neutral → Buy	$28
Jan-20-26	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$23
Jun-16-25	Upgrade	Piper Sandler	Neutral → Overweight	$2
Mar-17-25	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-14-25	Downgrade	Wedbush	Outperform → Neutral	$8 → $2
Mar-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Mar-14-25	Downgrade	BofA Securities	Buy → Underperform	$11 → $1
May-08-24	Initiated	BofA Securities	Buy	$12
Nov-09-23	Initiated	Deutsche Bank	Buy	$12
Oct-06-23	Initiated	Oppenheimer	Outperform	$10
Mar-21-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$15 → $8
Aug-18-22	Resumed	Wells Fargo	Overweight	$15
Jun-18-21	Initiated	H.C. Wainwright	Buy	$35
Dec-03-20	Initiated	Stifel	Buy	$25
Sep-02-20	Initiated	Jefferies	Buy	$21
Jul-16-20	Initiated	Wells Fargo	Overweight	$18

Show Previous Ratings

May-14-26 04:05PM	Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
Apr-30-26 09:36AM	Meta downgraded, Qualcomm upgraded: Wall Street's top analyst calls (The Fly)
Apr-19-26 07:45PM	Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026 (GlobeNewswire)
Apr-08-26 08:02PM	Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last? (Quartz) +5.21%
Apr-07-26 09:47AM	Arm downgraded, Arista Networks upgraded: Wall Street's top analyst calls (The Fly) +7.35%
04:05PM	Loading…
Mar-23-26 04:05PM	Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights (GlobeNewswire) +10.50%
Mar-03-26 05:10PM	Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +8.17%
Mar-02-26 03:28PM	Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock. (Barchart)
Feb-25-26 08:30AM	Sutro Biopharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-23-26 08:30AM	Sutro Biopharma Announces Participation at the 16th World ADC London Summit (GlobeNewswire)
Feb-11-26 07:25AM	Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains? (Zacks)
Feb-10-26 07:00AM	Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering (GlobeNewswire) +11.87%
Jan-22-26 06:15AM	Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock? (Zacks)
Jan-07-26 04:05PM	Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-25 07:55AM	Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines (PR Newswire) +11.76%
04:05PM	Loading…
Dec-17-25 04:05PM	Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -6.93%
Dec-16-25 04:05PM	Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-25 08:00AM	Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors (GlobeNewswire) +19.21%
Dec-01-25 08:00AM	Sutro Biopharma Announces 1-for-10 Reverse Stock Split (GlobeNewswire) -12.82%
Nov-12-25 10:00AM	Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day (GlobeNewswire)
Nov-06-25 06:25PM	Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -13.36%
04:30PM	Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Nov-05-25 04:05PM	Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025 (GlobeNewswire)
Nov-03-25 05:35PM	Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.27%
08:00AM	Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference (GlobeNewswire)
Sep-29-25 05:05PM	Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones (GlobeNewswire)
Aug-28-25 10:44AM	FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone (PR Newswire)
Aug-07-25 05:50PM	Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
05:10PM	Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:30PM	Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
08:00AM	Loading…
Jul-22-25 08:00AM	Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates (GlobeNewswire) +7.12%
Jun-24-25 02:07PM	Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last? (Zacks)
10:42AM	Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains? (Zacks)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
10:00AM	Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength? (Zacks)
07:56AM	RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains? (Zacks)
04:41AM	Strength Seen in Mobileye (MBLY): Can Its 11.6% Jump Turn into More Strength? (Zacks)
Jun-02-25 08:00AM	Sutro Biopharma Appoints Greg Chow as Chief Financial Officer (GlobeNewswire)
May-08-25 05:50PM	Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -9.06%
04:31PM	Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
May-07-25 08:25AM	EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-06-25 05:25PM	CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -9.51%
May-01-25 04:05PM	Sutro Biopharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
11:04AM	New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty (PR Newswire)
Apr-28-25 04:05PM	Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025 (GlobeNewswire)
Mar-18-25 09:45AM	Reddit initiated, Netflix upgraded: Wall Streets top analyst calls (TipRanks)
Mar-15-25 06:40PM	Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 (GlobeNewswire)
06:40PM	Sutro Biopharma Presents Data from Dose-Optimization Portion of REFR ME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 (GlobeNewswire)
09:40AM	Chipotle upgraded, Charter initiated: Wall Streets top analyst calls (TipRanks)
09:20AM	Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler (TipRanks)
Mar-14-25 03:00PM	Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ... (GuruFocus.com) -35.19%
08:18AM	Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs (GuruFocus.com)
07:57AM	Makary advances to full senate vote; Acelyrin, Pliant adopt poison pills (BioPharma Dive)
Mar-13-25 07:30PM	Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -6.72%
04:07PM	Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights (GlobeNewswire)
04:05PM	Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline (GlobeNewswire)
Mar-03-25 04:05PM	Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -9.75%
Jan-07-25 04:05PM	Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
09:00AM	Sutro Biopharma and Boehringer Ingelheim BioXcellence collaboration: Established first-in-class cell-free capabilities at commercial scale (GlobeNewswire)
Dec-10-24 08:00AM	Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRaME-O1 Trial in Platinum Resistant Ovarian Cancer (GlobeNewswire) -16.37%
08:00AM	Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFR ME-O1 Trial in Platinum Resistant Ovarian Cancer (GlobeNewswire)
Nov-18-24 12:00PM	Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-13-24 05:40PM	Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -12.88%
04:30PM	Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Nov-04-24 04:05PM	Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference (GlobeNewswire)
11:03AM	Sutro Biopharma begins trial of acute myeloid leukaemia treatment in children (Clinical Trials Arena)
Nov-01-24 08:00AM	Sutro Biopharma Announces Initiation of the Registration-enabling REFRaME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML (GlobeNewswire) +9.23%
08:00AM	Sutro Biopharma Announces Initiation of the Registration-enabling REFR ME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML (GlobeNewswire)
Oct-10-24 04:05PM	Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum (GlobeNewswire) +14.50%
Sep-20-24 04:01PM	Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-19-24 12:08PM	Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players (PR Newswire)
Sep-14-24 03:00AM	Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 (GlobeNewswire)
Sep-11-24 08:00AM	Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024 (GlobeNewswire)
Aug-26-24 10:48AM	Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why (Zacks)
Aug-23-24 07:03AM	Sutro Biopharma commences Phase II trial of luvelta for lung cancer (Clinical Trials Arena) +10.11%
Aug-22-24 08:00AM	Sutro Biopharma Announces Initiation of REFRaME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer (GlobeNewswire)
08:00AM	Sutro Biopharma Announces Initiation of REFR ME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer (GlobeNewswire)
Aug-13-24 05:45PM	Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +11.49%
04:30PM	Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
Jul-09-24 08:00AM	Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer (GlobeNewswire) +10.53%
May-19-24 09:03AM	Bank of America Predicts up to ~200% Surge for These 2 Strong Buy Stocks (TipRanks)
May-13-24 09:54PM	STRO Stock Earnings: Sutro Biopharma Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:38PM	Sutro Biopharma Q1 Loss Widens, Revenue Rises (MT Newswires)
04:30PM	Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
10:00AM	Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for (Zacks)
May-08-24 07:17AM	BofA Securities Starts Sutro Biopharma With Buy Rating (MT Newswires)
Apr-30-24 08:00AM	Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFR ME-O1 Trial (GlobeNewswire)
Apr-02-24 06:18AM	Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering (GlobeNewswire)
01:00AM	Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors (GlobeNewswire)
Mar-26-24 09:02PM	Sutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances (GuruFocus.com) +27.83% +17.94%
Mar-25-24 09:53PM	STRO Stock Earnings: Sutro Biopharma Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
06:30PM	Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates (Zacks)
04:30PM	Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire)
Mar-21-24 09:55AM	Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Feb-28-24 04:36AM	Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains? (Zacks)
Feb-06-24 04:05PM	Sutro Biopharma to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.37%
Jan-04-24 04:05PM	Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolR -targeting ADC (GlobeNewswire) -21.40%
Dec-14-23 04:05PM	Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR -targeted ADC, on January 4, 2024 (GlobeNewswire)
Dec-11-23 04:05PM	Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023 (GlobeNewswire)
Dec-04-23 04:05PM	Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit (GlobeNewswire)

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

CEO & DirectorMs. Jane Chung R.Ph.

CPAMr. Gregory K. Chow BA

Chief Scientific OfficerDr. Hans-Peter Gerber Ph.D.

Ph.D.Dr. James R. Swartz DSc

Senior Vice President of Technical OperationsMr. Devendra Luhar

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pauling David	Chief Admin. Ofcr. & GC	Mar 04 '26	Option Exercise	0.00	675	0	10,025	Mar 06 04:25 PM
Chung Jane	Chief Executive Officer	Mar 04 '26	Option Exercise	0.00	788	0	21,567	Mar 06 04:21 PM
Pauling David	Chief Admin. Ofcr. & GC	Mar 02 '26	Option Exercise	0.00	2,356	0	10,320	Mar 03 06:59 PM
Pauling David	Chief Admin. Ofcr. & GC	Mar 01 '26	Option Exercise	0.00	1,342	0	8,515	Mar 03 06:59 PM
Gerber Hans-Peter	CHIEF SCIENTIFIC OFFICER	Mar 02 '26	Option Exercise	0.00	2,843	0	10,688	Mar 03 06:56 PM
Gerber Hans-Peter	CHIEF SCIENTIFIC OFFICER	Mar 01 '26	Option Exercise	0.00	1,125	0	8,308	Mar 03 06:56 PM
Chung Jane	Chief Executive Officer	Mar 02 '26	Option Exercise	0.00	7,750	0	23,558	Mar 03 06:48 PM
Chung Jane	Chief Executive Officer	Mar 01 '26	Option Exercise	0.00	3,188	0	17,079	Mar 03 06:48 PM
BARBARA LEYMAN	Former Officer	Jan 20 '26	Proposed Sale	14.67	8,929	130,962		Jan 20 04:17 PM
Chung Jane	Chief Executive Officer	Dec 12 '25	Option Exercise	0.00	2,500	0	14,785	Dec 16 08:47 PM
Gerber Hans-Peter	CHIEF SCIENTIFIC OFFICER	Oct 15 '25	Buy	0.80	17,000	13,607	71,832	Oct 16 08:19 AM
Chow Gregory K.	CFO	Oct 15 '25	Buy	0.81	19,750	15,998	19,750	Oct 16 08:18 AM
Chung Jane	Chief Executive Officer	Oct 15 '25	Buy	0.80	12,500	10,011	122,850	Oct 16 08:17 AM
MATSUI CONNIE	Director	Oct 15 '25	Buy	0.80	50,000	39,950	50,000	Oct 16 08:15 AM
Pauling David	Chief Admin. Ofcr. & GC	Oct 15 '25	Buy	0.80	12,504	9,993	71,737	Oct 16 08:14 AM
Gerber Hans-Peter	CHIEF SCIENTIFIC OFFICER	Sep 18 '25	Option Exercise	0.00	37,500	0	68,249	Sep 22 05:01 PM
Leyman Barbara	Chief Business Officer	Jul 08 '25	Option Exercise	0.00	25,000	0	25,000	Aug 26 09:21 PM
Chung Jane	Chief Executive Officer	Aug 09 '25	Option Exercise	0.00	18,750	0	117,058	Aug 26 09:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

STRO

Sutro Biopharma Inc

Upgrade your Finviz experience